lu-208075 has been researched along with Hepatitis-C--Chronic* in 2 studies
2 other study(ies) available for lu-208075 and Hepatitis-C--Chronic
| Article | Year |
|---|---|
Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report.
Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD).. A 53-year-old woman with HIV/hepatitis C virus (HCV) co-infection, PAH and ESRD on regular hemodialyis was admitted in our hospital due to refractory heart failure while on treatment with bosentan (125 mg twice daily) and tadalafil (20 mg once daily) for PAH and antiretroviral treatment (cART) including darunavir/cobicistat (800/150 mg once daily). Excessive exposure to bosentan due to drug interactions between bosentan and darunavir/cobicistat was suspected. Bosentan was replaced by ambrisentan, with progressive improvement in her clinical condition. Pre- and postdialyzer cocentrations of ambrisentan in plasma were determined and hemodialysis extraction ratio for ambrisentan was 2%.. Our results suggest that hemodialysis results in minimal ambrisentan removal, and therefore no specific ambrisentan dosage adjustment seems to be required in ESRD patients undergoing hemodialysis. Topics: Antihypertensive Agents; Female; Hemodialysis Solutions; Hepatitis C, Chronic; HIV Infections; Humans; Hypertension, Pulmonary; Kidney Failure, Chronic; Middle Aged; Phenylpropionates; Pyridazines; Renal Dialysis | 2020 |
Pulmonary arterial hypertension associated with the use of interferon therapy for chronic hepatitis C infection complicated by extrinsic left main coronary artery compression.
Interferon-alpha treatment is a rare cause of pulmonary arterial hypertension (PAH). We report a case of a 43-year-old man treated for chronic hepatitis C infection complicated by decompensated right heart failure diagnosed with PAH and external coronary artery compression secondary to a dilated pulmonary trunk. The novel complication of extrinsic coronary artery compression should be considered in PAH patients presenting with chest pain or acute coronary syndrome. Establishing a diagnosis has clinical value as pulmonary vasodilator therapy may improve symptoms. Topics: Adult; Antiviral Agents; Chest Pain; Coronary Stenosis; Hepatitis C, Chronic; Humans; Hypertension, Pulmonary; Interferon-alpha; Male; Phenylpropionates; Pulmonary Artery; Pyridazines; Treatment Outcome; Vasodilator Agents | 2014 |